inMune Bio（纳斯达克股票代码：INMB）股价上涨9.6％

INmune Bio, Inc. (NASDAQ:INMB – Get Rating)'s share price traded up 9.6% during mid-day trading on Monday . The stock traded as high as $7.50 and last traded at $7.50. 30,587 shares traded hands during trading, a decline of 48% from the average session volume of 59,351 shares. The stock had previously closed at $6.84.

INmune Bio Stock Up 9.6 %

The company has a market capitalization of $134.60 million, a PE ratio of -4.93 and a beta of 1.93. The stock's fifty day moving average is $8.09 and its two-hundred day moving average is $7.50. The company has a current ratio of 5.92, a quick ratio of 5.92 and a debt-to-equity ratio of 0.16.

INmune Bio (NASDAQ:INMB – Get Rating) last issued its quarterly earnings results on Thursday, March 2nd. The company reported ($0.32) earnings per share (EPS) for the quarter. INmune Bio had a negative return on equity of 40.53% and a negative net margin of 7,299.20%. The company had revenue of $0.10 million for the quarter.

Institutional Investors Weigh In On INmune Bio

Several institutional investors have recently added to or reduced their stakes in INMB. Tower Research Capital LLC TRC purchased a new stake in INmune Bio during the 3rd quarter worth about $25,000. Advisor Group Holdings Inc. boosted its position in shares of INmune Bio by 52.9% in the fourth quarter. Advisor Group Holdings Inc. now owns 9,250 shares of the company's stock valued at $59,000 after acquiring an additional 3,200 shares during the period. Financial Advocates Investment Management bought a new position in shares of INmune Bio in the fourth quarter valued at approximately $87,000. Sepio Capital LP grew its stake in INmune Bio by 10.9% during the third quarter. Sepio Capital LP now owns 24,400 shares of the company's stock valued at $151,000 after acquiring an additional 2,400 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in INmune Bio during the 2nd quarter worth approximately $284,000. 10.66% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Company Profile

(Get Rating)

INmune Bio, Inc Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer's disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Featured Stories

• Get a free copy of the StockNews.com research report on INmune Bio (INMB)
• This Is Why Penny Stock GreenPower Motor Company Is A Win
• Comcast Sum of All Parts is Producing a Cumulative Effect
• The Greenbrier Companies: All Aboard For High-Yield In 2023
• Coty Stock is on the Comeback Trail
• Splunk Stock is an AI-Powered Enterprise SEIM Play

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.